NCT02471118 - Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions

Osteoarthritis, Knee

Interventions

DRUG

Adalimumab 40 mg

Adalimumab will be self-administered via subcutaneous (SC) injection

DRUG

Placebo

Placebo will be self-administered via subcutaneous (SC) injection

Trial Locations (7)

Division of Rheumatology, University of Alberta Hospital, Edmonton

Western University, London

The Ottawa Hospital, Ottawa

A.M.I.R., Montreal

GRMO Inc., Québec

CHUS Hotel-Dieu, Sherbrooke

Polmed Research Inc., Saskatoon